Description: Axcella is designing and developing AXA Candidates, compositions of endogenous metabolic modulators, or EMMs, engineered in distinct ratios, designed to target and maximize the fundamental role that EMMs play in regulating multiple metabolic functions. Axcella’s AXA Candidates are generated from its proprietary, human-focused AXA Development Platform. Axcella believes its expertise and capabilities in EMMs position it to become a preeminent biotechnology company reprogramming metabolism to address a diverse set of complex diseases and support health. Axcella’s AXA Development Platform has already produced a pipeline of product candidates in programs targeting liver, muscle and blood. Axcella was founded by Flagship Pioneering.
Home Page: www.axcellahealth.com
AXLA Technical Analysis
840 Memorial Drive
Cambridge,
MA
02139
United States
Phone:
857 320 2200
Officers
| Name | Title |
|---|---|
| Mr. William R. Hinshaw Jr. | Pres, CEO & Director |
| Dr. Alison D. Schecter M.D. | Pres of Strategy & Operations |
| Mr. David R. Epstein B.Sc., M.B.A. | Consultant |
| Mr. Laurent Chardonnet | Consultant |
| Mr. Robert W. Crane | Sr. VP & CFO |
| Dr. Paul Fehlner J.D., Ph.D. | Sr. VP, Chief Legal Officer & Corp. Sec. |
| Ms. Virginia R. Dean | Sr. VP & Chief People Officer |
| Dr. Larry Bell | Global Head of Regulatory Affairs & Pharmacovigilance and Sr. VP |
| Dr. Margaret James Koziel M.D. | Sr. VP & Chief Medical Officer |
| Mr. Dan Kirby | Sr. VP of Strategic Operations |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 8.7351 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2019-05-09 |
| Fiscal Year End: | December |
| Full Time Employees: | 59 |